Availability, prices, and affordability of selected essential cancer medicines in a middle-income country - the case of Mexico.
Daniela Moye-HolzMargaret EwenAnahí Cristina Dreser-MansillaSergio Bautista-ArredondoRené Soria-SaucedoJitse P van DijkSijmen A ReijneveldHans V HogerzeilPublished in: BMC health services research (2020)
The availability of essential cancer medicines, in the public and private sector, falls below World Health Organization's 80% target. The affordability remains suboptimal as well. A national health insurance scheme could serve as a mechanism to improve access to cancer medicines in the public sector. Comprehensive pricing policies are warranted to improve the affordability of cancer medicines in the private sector.